Tripos receives milestone payment for preclinical development

By Elaine Rigoli

Tampa, Fla., June 28 -Tripos Discovery Research, Ltd. has secured an undisclosed milestone payment from Chronogen Inc. as a result of a small-molecule drug-discovery collaboration progressing into preclinical development.

"We are finding Tripos' combination of proprietary informatics tools and medicinal chemistry expertise to be extremely valuable. This approach has substantially accelerated the identification and optimization of novel molecules for our key drug-discovery programs and delivered candidates with first-in-class potential," Chronogen chief executive officer Max Fehlmann said in a statement.

Tripos may receive further milestones as the newly discovered small molecules progress through clinical development.

Tripos Discovery Research, a division of Tripos, Inc., is based in Bude, England.

Chronogen is a drug-discovery company located in Montreal.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.